Aintzane Zabaleta Azpiroz

7PUBLICATIONS
104CO-AUTHORS
Medical mycologyHaematological tumoursInnate immunityMedical bacteriologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 24, 2026
MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma.

|Jun 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

|Jan 29, 2026
Immune biomarkers of increased infection risk in multiple myeloma.

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos

|Dec 17, 2025
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Tomas Jelinek, David Zihala, Aintzane Zabaleta

|Nov 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

Aintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena

|May 30, 2024
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Esperanza Martín-Sánchez, Laura Blanco, Peter S Kim

Pageof 2

Frequent Collaborators

6 joint publications

Bruno Paiva

4 joint publications

Jesús San-Miguel

4 joint publications

Joaquín Martínez-López

4 joint publications

Paula Rodríguez-Otero